Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus

Atherosclerosis

Volumn 166, Issue 1, 2003, Pages 129-135

  Van de Ree, M A ^a   Huisman, M V ^a   Princen, H M G ^b   Meinders, A E ^a   Kluft, C ^b   Berk Planken, I ^c   Hoogerbrugge, N ^c   Jansen H , ^d   Stolk, R P ^e   Van Venrooij, F V ^e   Banga, J D ^e   Dallinga Thie, G ^e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Diabetes mellitus; Inflammation; Risk factors

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; INTERLEUKIN 6; LIPID; PLACEBO; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HEART PROTECTION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; BODY MASS; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; BODY MASS INDEX; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; MALE; MIDDLE AGED; PYRROLES; TREATMENT OUTCOME;

EID: 0037212882     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(02)00316-7     Document Type: Article

References (31)

1. Haverkate F., Thompson S.G., Pyke S.D., Gallimore J.R., Pepys M.B. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 349:(9050):1997;462-466.
2. Ridker P.M., Glynn R.J., Hennekens C.H. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 97:(20):1998;2007-2011.
3. Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. New Engl. J. Med. 342:(12):2000;836-843.
4. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br. Med. J. 321:(7255):2000;199-204.
5. Torzewski M., Rist C., Mortensen R.F., Zwaka T.P., Bienek M., Waltenberger J., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 20:(9):2000;2094-2099.
6. Zwaka T.P., Hombach V., Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 103:(9):2001;1194-1197.
7. Jager A., van Hinsbergh V.W., Kostense P.J., Emeis J.J., Yudkin J.S., Nijpels G., et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. Arterioscler. Thromb. Vasc. Biol. 19:(12):1999;3071-3078.
8. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 100:(3):1999;230-235.
9. Strandberg T.E., Vanhanen H., Tikkanen M.J. Associations between change in C-reactive protein and serum lipids during statin treatment. Ann. Med. 32:(8):2000;579-583.
10. Cortellaro M., Cofrancesco E., Boschetti C., Cortellaro F., Mancini M., Mariani M., et al. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, t-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin alone and in combination treatment. Thromb. Haemost. 83:(4):2000;549-553.
11. Kluft C., de Maat M.P., Gevers Leuven J.A., Potter van Loon B.J., Mohrschladt M.F. Statins and C-reactive protein. Lancet. 353:(9160):1999;1274.
12. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation. 103:(9):2001;1191-1193.
13. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F.M., Moye L.A., Goldman S., et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation. 98:(9):1998;839-844.
14. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI Study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diab. Care. 24:(8):2001;1335-1341.
15. de Maat M.P., de Bart A.C., Hennis B.C., Meijer P., Havelaar A.C., Mulder P.G., et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler. Thromb. Vasc. Biol. 16:(9):1996;1156-1162.
16. Rifai N., Tracy R.P., Ridker P.M. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin. Chem. 45:(12):1999;2136-2141.
17. Hutchinson W.L., Koenig W., Frohlich M., Sund M., Lowe G.D., Pepys M.B. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin. Chem. 46:(7):2000;934-938.
18. Kluft C., Meijer P., Brussaard H.E., Krans H.M., Schuit A.J. Serum neopterin in acute coronary syndromes. Lancet. 349:(9060):1997;1253.
19. Packard C.J., O'Reilly D.S., Caslake M.J., McMahon A.D., Docherty G., Ford I., et al. Lipoprotein-associated phospholipase A(sub 2) as an independent predictor of coronary heart disease. New Engl. J. Med. 343:(16):2000;1148-1155.
20. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl. J. Med. 339:(4):1998;229-234.
21. Tan K.C., Chow W.S., Tam S.C., Ai V.H., Lam C.H., Lam K.S. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 87:(2):2002;563-568.
22. Weinhold B., Ruther U. Interleukin-6-dependent and -independent regulation of the human C-reactive protein gene. Biochem. J. 327:(Pt 2):1997;425-429.
23. Inoue I., Goto S., Mizotani K., Awata T., Mastunaga T., Kawai S., et al. Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of MRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor alpha (PPARalpha) in primary endothelial cells. Life Sci. 67:(8):2000;863-876.
24. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J. Clin. Invest. 107:(11):2001;1423-1432.
25. Chinetti G., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall. Z. Kardiol. 90:(Suppl. 3):2001;125-132.
26. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391:(6662):1998;79-82.
27. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:(6662):1998;82-86.
28. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274:(45):1999;32048-32054.
29. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 103:(15):2001;1933-1935.
30. Deskur-Smielecka E., Wykretowicz A., Kempa M., Furmaniuk J., Wysocki H. The influence of short-term treatment with simvastatin on the inflammatory profile of patients with hypercholesterolaemia. Coron. Artery Dis. 12:(2):2001;143-148.
31. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. J. Am. Med. Assoc. 282:(22):1999;2131-2135.